Neurocrine Biosciences (NBIX) CLO Lippoldt Buys $16K of Stock

On June 26, 2026, Darin Lippoldt, the Chief Legal Officer of NBIX, purchased 200 shares of the company's stock at an average price of $81.49. This transaction, not made under a pre-planned arrangement, amounted to a total value of $16,298.

What Changed in Darin Lippoldt's NBIX Position

Lippoldt's purchase of 200 shares marks a direct investment in NBIX. This transaction was completed at a price of $81.49 per share, demonstrating his confidence in the company's prospects.

Other Institutional Activity in NBIX

Several major institutional investors have also adjusted their positions in NBIX. BlackRock, Inc. increased its holdings by 555,010 shares, bringing its total to 13,385,607 shares worth approximately $1.76 billion. JPMorgan Chase & Co. added 241,711 shares, now holding 5,442,067 shares valued at about $700.5 million. On the other hand, Dodge & Cox slightly reduced its position by 47,005 shares, maintaining 5,461,037 shares worth $719.4 million. AQR Capital Management LLC made a significant move by increasing its stake by 1,667,261 shares, a 51% increase, totaling 4,938,967 shares valued at $650.7 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, with 4,726,344 and 4,511,904 shares, respectively.

Neurocrine Biosciences, Inc. Stock Up 24.1%

Shares of NBIX traded near $170 on Wednesday. The stock has seen interest from both institutional investors and analysts alike, reflecting its active presence in the market.

Insider Buying and Selling at Neurocrine Biosciences, Inc.

Darin Lippoldt, in addition to his recent purchase, executed several other transactions. On June 29, 2026, he sold 9,800 shares at a price of $170.16 per share, and another planned sale occurred at $169.57 per share.

Analysts Set New Price Targets

Analysts continue to show strong support for NBIX. On June 2, 2026, Goldman Sachs reinstated its buy rating with a target price of $213. RBC Capital maintained its buy rating with a target of $183 on May 29, 2026. Bernstein initiated coverage with a buy rating and a target of $221 on May 22, 2026. The consensus remains bullish, with a strong buy recommendation and a range of target prices from various analysts.

Bottom Line

Darin Lippoldt's recent purchase of NBIX shares adds to the positive sentiment surrounding the company, as reflected by institutional moves and analyst ratings. While insider transactions provide insight into management's outlook, 13F filings and analyst reports offer a broader view of market sentiment. Investors often track these activities to gauge the confidence levels of those closest to the company's operations and its financial health.